Available clinical trials for mild cognitive impairment

CARPE DIEM Study: Cognition, Age and Rapamycin Effectiveness-Downregulation of the mTor Pathway
The purpose of this study is to evaluate if if the drug, Rapamycin, will reach the brain and effectively treat symptoms of Alzheimer’s disease and mild cognitive impairment using cerebrospinal fluid.

Eligibility: Adults, ages 55 to 85, diagnosed with mild cognitive impairment or early stages of Alzheimer’s disease
Learn more

 

MIND Study: Memory Improvement Through Nicotine Dosing 
The purpose of this study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with mild cognitive impairment (MCI).

Eligibility: Healthy, non-smoking adults, age 55+ who notice changes in their memory or whose family member notice changes.
Learn more